Related by context. All words. (Click for frequent words.) 80 ADAS Cog 79 Alzheimer Disease Assessment 75 Scale cognitive subscale 75 UPDRS 74 Rating Scale MADRS 73 HAQ DI 73 Montgomery Asberg Depression 73 MADRS score 73 YMRS 73 PANSS 73 Unified Parkinson Disease 73 PANSS total 72 ADCS ADL 72 Montgomery Åsberg Depression 72 MMSE score 72 MADRS 71 MMSE 71 NIHSS 71 Crohn Disease Activity 71 CIBIC plus 70 ADCS CGIC 70 WOMAC pain 70 NIH CPSI 70 HDRS 70 Brief Psychiatric 70 IBDQ 69 ADHD RS 69 lumbar spine BMD 69 State Examination MMSE 68 Rating Scale UPDRS 68 Y BOCS 68 Negative Syndrome 68 CNS LS 68 IRLS 68 Severity MSCS score 67 HOMA IR 67 Visual Analogue Scale VAS 67 UPDRS motor 67 Scale EDSS 67 Neuropsychiatric Inventory NPI 67 CDAI score 67 symptom severity 67 ADHD Rating Scale 67 mRS 67 liver histology 67 Index CDAI 67 virologic response 67 Psoriasis Area 67 mTSS 67 TNSS 66 EQ 5D 66 Scale PANSS 66 subscore 66 Score IPSS 66 HAMD 66 IPSS 66 Hamilton Rating Scale 66 depressive symptom 66 BMI z 66 Subgroup analysis 65 Fibromyalgia Impact Questionnaire 65 Expanded Disability Status 65 Visual Analog Scale 65 Neuropsychiatric Inventory 65 Global Impression CGI 65 IRLS score 65 SGRQ 65 clinically meaningful improvement 65 HAM D# 65 International Prostate Symptom 65 Score DAS# 65 trough FEV1 65 subscale scores 65 Rating Scale BPRS 64 EDSS score 64 BPH Symptom Score 64 WOMAC 64 Pain Intensity 64 Health Assessment Questionnaire 64 6MWD 64 CDAI 64 Kaplan Meier analysis 64 achieved statistical significance 64 NYHA functional class 64 Secondary endpoints included 64 PASI scores 64 APACHE II 64 Global Impression 64 Secondary endpoints 64 demonstrated clinically meaningful 64 Index CDAI score 64 Ocular Surface Disease 64 subscores 64 HAM D 64 posttreatment 64 nasal symptom 64 Scale Cognitive Subscale 64 postintervention 64 univariate 64 DAS# scores 63 QIDS SR 63 biopsy Gleason 63 QoL 63 QTcF 63 CI -#.# 63 tipranavir r 63 HADS 63 DAS# [002] 63 ANOVA 63 Visual Analog 63 8mg/kg 63 HbA 1c levels 63 mg BID dose 63 DLQI 63 MoxDuo TM IR 63 multivariate Cox 63 p = .# [002] 63 virological response 63 XIENCE V PROMUS Stent 63 Primary endpoints 63 Score TOS 63 ‰ ¥ 63 SELENA SLEDAI 63 4mg/kg 63 posttest 63 LVEF 63 DAS# remission 63 Knodell necroinflammatory score 63 Severity Index PASI 63 desvenlafaxine succinate 63 CR nPR 63 PANSS scores 62 subscales 62 methotrexate monotherapy 62 Status Scale EDSS 62 Mean Symptom Complex 62 unpaired t 62 adjunctive placebo 62 DAS# CRP 62 PSADT 62 Brief Pain 62 lopinavir r arm 62 HRQL 62 HBeAg negative patients 62 morphometric vertebral fractures 62 Descriptive statistics 62 -#.# mg dL [002] 62 CORE OM 62 Disease Activity 62 Non inferiority 62 Rating Scale 62 SELENA SLEDAI score 62 PSQI 62 hemoglobin A1c levels 62 attain statistical significance 62 AUA Symptom Score 62 CFQ R 62 MMSE scores 62 BPRS 62 -#.# ± [002] 62 placebo p = 62 Likert pain 62 Clinician Administered PTSD 62 P = .# 62 symptomatic VTE 62 EDSS scores 62 HBeAg seroconversion 62 -#.# mg dL [001] 61 HRQoL 61 ALS Functional 61 logistic regression analyzes 61 prospectively defined 61 serologically active patients 61 albumin excretion rate 61 eszopiclone 61 placebo p 61 baseline HbA1c 61 venlafaxine XR 61 affective psychosis 61 ANCOVA 61 ALSFRS R 61 IIEF 61 CCyR 61 NIHSS score 61 Pain Rating Scale 61 HbA1C levels 61 GAMMAGARD 61 Inventory BPI 61 HbA1c levels 61 statistically significant p = 61 interrater reliability 61 FACIT Fatigue 61 ACR# response 61 Mini Mental 61 serum phosphorous 61 adjunctive ABILIFY 61 binary logistic regression 61 HbA 1c 61 -#.# log# 61 lispro 61 achieved ACR# 61 IELT 61 State Exam MMSE 61 WOMAC TM 61 sd = 61 Visual acuity 61 EDSS 61 Oswestry Disability Index 61 preoperative PSA 61 postprocedure 61 fasting plasma glucose FPG 61 secondary efficacy endpoint 61 tapentadol ER 61 creatinine clearance 61 baseline FEV 61 paricalcitol 61 Key secondary endpoints 61 ± SD 61 nerve conduction velocity 61 Bonferroni correction 61 multivariable analysis 61 serum urate 61 Depression Rating Scale 61 F FDG PET 61 QTc 61 non menstrual pelvic 61 neurologic progression 61 oxycodone CR 61 WAIS III 61 Mania Rating Scale 61 metabolic parameters 61 univariate analyzes 61 mg TID 61 Ishak fibrosis score 61 urinary N telopeptide 60 certolizumab 60 genotypic resistance 60 cardiac autonomic 60 PCWP 60 Secondary efficacy endpoints 60 LOCF 60 extrapyramidal symptoms 60 clinically meaningful improvements 60 noninferiority 60 spirometric 60 carotid IMT 60 BPH symptom 60 Secondary endpoints include 60 variance ANOVA 60 serum HBV DNA 60 pCR 60 CHADS2 60 CIBIC + 60 apnea hypopnea index 60 prespecified secondary 60 bivariate 60 KOOS 60 intima media thickness 60 NIS LL 60 confidence intervals CIs 60 logistic regression model 60 Hb A1C 60 viral kinetics 60 haloperidol 60 binary restenosis 60 intraobserver 60 % Confidence Interval 60 covariate 60 Wilcoxon rank sum 60 = #.#-#.# 60 SSRI SNRI 60 highly emetogenic 60 plus methotrexate 60 Histologic 60 undetectable HBV DNA 60 Physical Component 60 definite stent thrombosis 60 logistic regression models 60 Symptom severity 60 periprocedural 60 dactylitis 60 aspartate aminotransferase AST 60 Pred Forte 60 relapsed MM 60 isoprostane 60 endometrial thickness 60 progression TTP 60 premorbid 60 PREZISTA r arm 60 neurocognitive function 60 interobserver reliability 60 ETDRS 60 Erectile Function IIEF 60 multivariate analyzes 60 logistic regression analysis 60 amisulpride 60 PSA nadir 60 Thrombolysis 60 atheroma volume 60 Free Survival PFS 60 #mg/day [001] 60 sustained virological response 60 eplerenone 60 SVR# 60 biochemical relapse 60 euthymic patients 60 peak VO2 60 nondiabetic patients 60 Geriatric Depression 60 Median PFS 60 fasting insulin 60 antipsychotic efficacy 60 subthreshold depression 60 endoscopic remission 60 dyssynchrony 59 NPH insulin 59 Kaplan Meier estimates 59 covariance ANCOVA 59 serum aminotransferase levels 59 timepoints 59 mg QD 59 REYATAZ r arm 59 bronchial hyperresponsiveness 59 CANCIDAS 59 radiographic progression 59 -#.# log# copies mL 59 preoperatively 59 plus MTX 59 prospectively stratified 59 p = .# [001] 59 glycosylated hemoglobin levels 59 sUA 59 mL/min/#.# m 2 59 abacavir lamivudine 59 receiving golimumab 59 moderate renal impairment 59 Pharmacokinetic parameters 59 INVEGA ® 59 Hamilton Anxiety Scale 59 FDA defined valvulopathy 59 DLTs 59 aMCI 59 myocardial viability 59 methacholine challenge 59 CIMZIA TM certolizumab pegol 59 T2DM 59 Main Outcome Measures 59 tolterodine ER 59 aPTT 59 Functioning GAF 59 aminotransferase levels 59 intact parathyroid hormone 59 biochemical recurrence 59 mg ustekinumab 59 Subgroup analyzes 59 Glasgow Coma Scale 59 virologic 59 â ‰ ¥ 59 glycosylated hemoglobin HbA1c 59 gadolinium enhancing lesions 59 fasting plasma glucose 59 interobserver 59 UPDRS II 59 myocardial reperfusion 59 Univariate 59 GERD symptom 59 docetaxel pretreated 59 insulin detemir 59 FEV1 59 nondepressed 59 hematological parameters 59 PERMP 59 tocilizumab 59 MDRD 59 Sustained virologic response 59 adenoma recurrence 59 chi squared 59 HBeAg 59 SF #v# 59 glycated hemoglobin levels 59 baseline A1C 59 FOLFOX4 59 Hemoglobin A1c 59 prespecified 59 mcg QD 59 glycated hemoglobin 59 platelet reactivity 59 Scale EDSS score 59 left ventricular diastolic 59 % CI #.#-#.# [003] 59 postdose 59 virologic responses 59 timepoint 59 tiotropium 59 Ashworth Scale 59 Distress Scale 59 SUVmax 59 Kaplan Meier survival 59 OGTT 58 CONCERTA ® 58 QRS duration 58 Kaplan Meier curves 58 corneal staining 58 eNO 58 subanalysis 58 alanine aminotransferase ALT 58 preintervention 58 allele frequencies 58 convergent validity 58 WOMAC scores 58 Postoperatively 58 psychosocial functioning 58 multiple linear regression 58 abdominal pain abdominal discomfort 58 CPAP adherence 58 Viral load 58 UPDRS Part III 58 multivariate logistic regression 58 lipid parameters 58 ACR Pedi 58 RLAI 58 tolvaptan 58 Score DAS 58 LV ejection fraction 58 Target Lesion Revascularization TLR 58 neostigmine 58 corrected QT interval 58 secondary endpoint 58 Ejection Fraction 58 univariate analysis 58 NNT = 58 activated partial thromboplastin 58 NLX P# 58 serum urate levels 58 exploratory endpoints 58 rosuvastatin #mg 58 bosentan 58 CrCl 58 Pearson correlation coefficient 58 #.#mg/dL 58 logistic regression 58 complete cytogenetic response 58 Capacity FVC 58 Treatment Diabetic Retinopathy 58 ug kg 58 retest reliability 58 pharmacokinetic PK profile 58 AST ALT 58 Kruskal Wallis test 58 Erectile Function 58 mg XP# 58 mg kg dose 58 lamivudine refractory patients 58 hemoglobin A1c HbA1c 58 Negative Symptoms 58 APTIVUS r 58 tirofiban 58 rotigotine 58 intraclass correlation coefficient 58 estimated GFR 58 treat NNT 58 ARB telmisartan 58 confirmed CCyR 58 TEAEs 58 Kaplan Meier 58 TPV r 58 solifenacin 58 serum magnesium 58 FDG uptake 58 ABC/3TC 58 ACR# responses 58 budesonide pMDI 58 leukocyte count 58 Depression Inventory 58 dapagliflozin plus 58 achieved PASI 58 specific antigen PSA 58 BENICAR HCT 58 pretreatment baseline 58 pairwise comparisons 58 femoral neck BMD 58 p = NS 58 atorvastatin #mg 58 HER2 expression 58 interobserver agreement 58 annualized relapse 58 hematologic parameters 58 HbA 1C 58 divalproex sodium 58 p = #.# [002] 58 tapentadol IR 58 aminotransferases 58 Endothelial function 58 Cockcroft Gault 58 FDG-PET/CT 58 glatiramer acetate 58 pulmonary capillary wedge 58 receiving ISENTRESS 58 point Likert scale 58 antibody titer 58 fructosamine 58 bortezomib refractory 58 Postoperative 58 glomerular filtration rate 58 pramipexole 58 STN stimulation 58 multivariable Cox 58 Poisson regression 58 #mg/day [002] 58 ± SEM 58 ACTEMRA TM 58 baseline LDH 58 Cronbach alpha 58 Platelet counts 58 #Gy 58 Kaplan Meier method 58 Cystic Fibrosis Questionnaire Revised 58 BILAG 58 conditional logistic regression 58 RECIST Response Evaluation Criteria 57 Prognostic 57 creatinine ratio 57 PREZISTA ritonavir 57 serum phosphorus 57 refractory ischemia 57 EORTC QLQ C# 57 Lucentis monotherapy 57 donepezil 57 cognitive affective 57 haematologic 57 APOE genotype 57 hip BMD 57 HRQOL 57 STRIDE PD 57 apolipoprotein B 57 FOLFOX6 57 mucosal healing 57 Doxil ® 57 serum HCV RNA 57 fluticasone salmeterol 57 sustained virologic response 57 paliperidone ER 57 MCyR 57 racemic albuterol 57 colorectal adenoma 57 idiopathic Parkinson disease 57 VELCADE melphalan 57 TAXUS Express Stent 57 undetectable HCV RNA 57 clinically meaningful reductions 57 calculated creatinine clearance 57 mg BID 57 Symptom Checklist 57 nonparametric 57 unfractionated heparin 57 postop 57 Timed Walk 57 PEG IFN 57 achieved CCyR 57 multicentre randomized 57 periprocedural MI 57 Tasigna prolongs 57 pegylated interferon alfa 2b 57 Pegasys ® 57 neutropaenia 57 echocardiographic parameters 57 Operative mortality 57 safinamide 57 μmol L 57 mg Proellex 57 posttransplant 57 severe neutropenia 57 dexmedetomidine 57 erection hardness 57 mean ± SEM 57 mRCC 57 Wechsler Adult 57 NATRECOR R 57 icatibant 57 evaluable subjects 57 hours postdose 57 % CI #.#-#.# [007] 57 dyspnoea 57 histological subtype 57 #mg QD [002] 57 salivary cortisol 57 serum prostate 57 LV dysfunction 57 salmeterol fluticasone propionate 57 nonobese 57 FFNS 57 donepezil Aricept 57 hippocampal volume 57 VKORC1 57 clomipramine 57 PSA kinetics 57 TLUS 57 primary percutaneous coronary 57 Pharmacodynamic 57 T2 lesions 57 virologic failure 57 glomerular filtration 57 p = #.# [003] 57 anemia hemoglobin 57 HBV DNA levels 57 dosing cohort 57 Forced Vital 57 statistically significant p 57 symptom exacerbation 57 EURIDIS 57 μg kg 57 A1c levels 57 dichotomized 57 linaclotide treated 57 FACIT 57 elevated ALT 57 #.#/#.# mmHg [001] 57 Depressive symptoms 57 Nesiritide 57 Baseline characteristics 57 Scale CNS 57 oxycodone IR 57 alanine aminotransferase 57 LS BMD 57 Insulin sensitivity 57 R# #mg BID 57 dose proportionality 57 composite endpoint 57 ACR# ACR# 57 KRAS mutant tumors 57 oral FTY# 57 HIV RNA 57 detectable HCV RNA 57 urodynamic parameters 57 angiographic outcomes 57 intravaginal ejaculatory latency 57 antidepressant efficacy 57 enthesitis 57 Treatment Outcome 57 EDEMA3 trial 57 amnestic mild cognitive impairment 57 QTc interval 57 electrophysiologic 57 meta analytic 57 arterial oxygen saturation 57 urine albumin 57 baseline PASI 57 carotid intima media 57 #q# deletion syndrome 57 poststroke 57 TURBT 57 ipsilateral stroke 57 AUC0 57 placebo fluoxetine 57 concomitant medications 57 infarct size 57 octreotide LAR 57 bivalirudin monotherapy 57 lispro alone 57 Response Evaluation Criteria 57 AUA BPH Symptom Score 57 titrated glipizide 57 rFSH 57 multivariate regression analysis 57 receiving VICTRELIS 57 clinical endpoints 57 mg qd 57 HBeAg positive 57 doxorubicin docetaxel 57 plasma HCV RNA 57 QD dosing 57 cells mcL 57 p = #.# [004] 57 generalized estimating 57 #.#mmHg 57 -#.# ± [001] 57 somatic symptom 57 Interrater reliability 57 -5 -6 57 dose atorvastatin 57 ritonavir boosted 57 UPDRS scores 57 lymphopenia 57 glycated hemoglobin HbA1c 57 FOLPI 57 CIMZIA ™ 57 mg/m2 dose 57 semiquantitative 57 blood Phe levels 57 Fasting plasma glucose 57 AGILECT ® 57 prognostic variables 57 subtest 57 Cholinesterase Inhibitors 57 serum potassium 56 nadroparin 56 PsA 56 IKDC 56 Lupuzor ™ 56 alicaforsen enema 56 response CCyR 56 Rating Scale IRLS 56 mcg albinterferon alfa 2b 56 SCr 56 left ventricular LV 56 serum cortisol 56 nonsignificant 56 heterozygotes 56 thyroglobulin 56 cortical activation 56 transaminase levels 56 TMC# r 56 fractional anisotropy 56 subthreshold 56 diameter stenosis 56 serum testosterone 56 5-FU/LV 56 adalimumab 56 sensitivity specificity 56 ribavirin RBV 56 Major Adverse Cardiac 56 generalized anxiety disorder GAD 56 dalteparin 56 regression coefficient 56 Epworth Sleepiness Scale 56 recurrent GBM 56 sirolimus eluting stent 56 Likert scale 56 bi ventricular pacing 56 ACR# [002] 56 serum BDNF 56 estimated glomerular filtration 56 #μg [001] 56 Taxus Stent 56 lactate dehydrogenase LDH 56 leukocyte counts 56 albumin excretion 56 covariance 56 quetiapine XR 56 SGPT 56 comparator arm 56 demonstrated statistically significant 56 AGILECT R 56 quetiapine 56 #mg dose [002] 56 Stent thrombosis 56 Bonferroni 56 Pemetrexed 56 multivariable logistic regression 56 pyridostigmine 56 log# copies mL 56 pT3 56 CIMZIA TM 56 postoperative complication 56 lopinavir r 56 TIMP 1 56 Logistic regression 56 HSCT 56 CD4 + cell 56 seropositive patients 56 prednisone prednisolone plus 56 reboxetine 56 TIMI 56 left ventricular systolic 56 Univariate analysis 56 randomized multicenter trial 56 irbesartan 56 lacosamide 56 unfractionated heparin UFH 56 alteplase 56 plus prednisone 56 CHADS 56 histologic 56 chemoradiation therapy 56 serum clusterin levels 56 syndromal 56 galiximab 56 NMIBC 56 dyspnea 56 hsCRP levels 56 coronary stenosis 56 statistical significance p 56 neutrophil counts 56 laboratory abnormalities 56 adenotonsillectomy 56 Kaplan Meier curve 56 Beck Anxiety Inventory 56 PANSS Positive 56 somatostatin analog 56 Cypher Stent 56 nicardipine 56 CIPN 56 ziprasidone 56 ULORIC 56 glycosylated hemoglobin 56 oral anticoagulation 56 intravenous cyclophosphamide 56 lymphocytosis 56 experienced virologic failure 56 Main Outcome Measure 56 mean baseline A1C 56 etanercept 56 Alzheimer Disease Cooperative 56 microalbuminuria 56 aldosterone antagonist 56 citalopram 56 MetS 56 bivariate analysis 56 FFR guided treatment 56 Seattle Angina Questionnaire 56 gadolinium enhancing 56 interquartile range 56 SYNTAX 56 clinically meaningful 56 clinicopathological features 56 Preoperatively 56 orthostatic 56 log# reduction 56 kidney allograft 56 interferon ribavirin 56 echocardiographic 56 secondary efficacy endpoints 56 χ 56 systolic function 56 iloprost 56 ejection fractions 56 plus dexamethasone 56 blood Phe 56 Clinician Interview Based 56 Follicular Lymphoma 56 serum phosphate 56 hepatic enzyme 56 EBMT criteria 56 seroprotection 56 cortical atrophy 56 Likert 56 ischemia driven 56 pain subscale 56 CIN2 + 56 canakinumab 56 RAPAFLO R 56 QTc intervals 56 Solid Tumors criteria 56 serum PSA 56 Decitabine 56 nonfatal MI 56 nonresponders 56 Omacetaxine mepesuccinate 56 Lantus ® 56 tipranavir ritonavir 56 electrocardiographic 56 CIN3 56 ROC curves 56 Genant modified Sharp 56 troponin T 56 actigraphy 56 ALT elevation 56 oxcarbazepine 56 Stroke Scale 56 serum IGF 56 Prognostic Index 56 serum estradiol 56 GSK# [001] 56 untreated psychosis 56 mCi kg 56 CC genotype 55 Glomerular filtration rate 55 corticosteroid dose 55 postoperative chemotherapy 55 correlation coefficients 55 ancrod 55 primary aldosteronism 55 FOLFIRI 55 Angiographic 55 sUA levels 55 multicenter randomized placebo controlled 55 Myocardial Infarction Study 55 Ki# 55 fraction LVEF 55 death reinfarction 55 vitreous haze 55 Relieve Depression STAR 55 odds ratios ORs 55 retinal thickness 55 Flu Cy 55 aripiprazole 55 tranylcypromine 55 Myocardial Infarction TIMI 55 zonisamide SR 55 Total Nasal Symptom 55 Clinically meaningful 55 expiratory flow 55 mcg Albuferon 55 macroalbuminuria 55 Mental Component 55 non squamous histology 55 weekly CSBMs 55 brachial artery flow 55 psychometric properties 55 chlorambucil 55 Hazard Ratio HR 55 Eur J Endocrinol 55 rhinoconjunctivitis 55 lamotrigine 55 hemodynamic measurements 55 Dyspnea 55 recurrent glioblastoma multiforme 55 Bosentan 55 sargramostim 55 erythrocyte sedimentation rate 55 spontaneous bowel movements 55 neuroleptic 55 active comparator 55 nonmetastatic prostate cancer 55 d dimer 55 multivariable adjusted 55 TAXUS p value 55 mmol l 55 IFN α 55 splenectomized patients 55 HbA1C 55 BPRS PSS 55 tumor histology 55 serum lipid 55 Apgar scores 55 gadolinium enhanced 55 noninferior 55 IFN alfa 55 subsyndromal depression 55 mcg kg 55 alexithymia 55 cognitive domains 55 sirolimus eluting stents 55 creatine kinase MB 55 PREZISTA r 55 Randomized Evaluation 55 Chronic Illness Therapy 55 System IPSS 55 CRp 55 SSRI citalopram 55 Primary Endpoint 55 mediated dilation 55 akinesia 55 somatic symptoms 55 D dimer 55 uncorrected visual acuity 55 TDF FTC 55 hypofractionated radiation 55 FDG PET imaging 55 plasma folate 55 Randomized clinical trials 55 pentoxifylline 55 complete cytogenetic 55 p ≤ 55 serum ALT 55 ug dose 55 IOP lowering 55 mEq L 55 mg tid 55 PHQ 9 55 CLARITY study 55 ASIA Impairment 55 Endocrine Therapy 55 KCCQ 55 ertapenem 55 Prospective Randomized Trial 55 hemoglobin Hb 55 overnight polysomnography 55 hemoglobin concentrations 55 #.#ng/ml 55 fractional shortening 55 colesevelam HCl 55 emotional lability 55 transaminase elevations 55 virologic suppression 55 Pegylated Liposomal Doxorubicin 55 baseline FEV1 55 crizotinib PF # 55 hypomagnesemia 55 PCa 55 QTc prolongation 55 Functional Assessment 55 mg/m2 cohort 55 preoperative chemotherapy 55 fosamprenavir 55 postoperatively 55 lumbar spine bone 55 urate lowering therapy 55 oral olanzapine 55 clodronate 55 liver metastasis 55 Haptoglobin 55 baseline CD4 + 55 microg 55 MIRAPEX 55 zolmitriptan 55 plasma pharmacokinetics 55 CK MB 55 -#.# mmHg